How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

62 results for

ISTH Bleeding Assessment Tool

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. (PubMed)

Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. Bleeding assessment tools (BAT) have been widely implemented in the work-up of patients with suspected bleeding disorders. However, diagnostic BAT utility regarding platelet function disorders is still elusive.We aimed to assess the diagnostic value of the International Society on Thrombosis and Haemostasis BAT (ISTH-BAT) for platelet function disorders in clinical practice.The (...) clinical characteristics and laboratory data of all consecutive patients referred between January 2012 and March 2017 to an outpatient unit of a university hospital with a suspected bleeding disorder were prospectively collected. The diagnostic work-up was performed according to current recommendations following a pre-specified protocol and platelet function was tested using light transmission aggregometry as well as flow cytometry.Five hundred and fifty-five patients were assessed, 66.9% were female

2019 Journal of Thrombosis and Haemostasis

2. The international society on thrombosis and haemostasis-bleeding assessment tool (ISTH-BAT) and the risk of future bleeding. (Full text)

The international society on thrombosis and haemostasis-bleeding assessment tool (ISTH-BAT) and the risk of future bleeding. Essentials ISTH Bleeding Assessment Tool (ISTH-BAT) is used to assist the diagnosis of bleeding disorders. We examined whether the ISTH-BAT is capable of predicting the risk of future bleeding. 136 subjects were administered the ISTH-BAT and followed for up to four years. The ISTH-BAT score failed to predict the risk of future bleeding.Background The ISTH Bleeding (...) Assessment Tool (ISTH-BAT) is a diagnostic tool used in subjects with suspected inherited bleeding disorders. Aim To evaluate whether the ISTH-BAT, applied at first work-up in a tertiary-care center, predicts the risk of subsequent bleeding events. Methods This was an observational cohort study including all consecutive subjects, of either sex and any age, referred between 2011 and 2015 because of a suspected bleeding disorder. The analysis was restricted to those with an ISTH-BAT score of ≥ 3. Incidence

2017 Journal of Thrombosis and Haemostasis PubMed

3. ISTH Bleeding Assessment Tool

ISTH Bleeding Assessment Tool ISTH Bleeding Assessment Tool Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 ISTH Bleeding Assessment (...) Tool ISTH Bleeding Assessment Tool Aka: ISTH Bleeding Assessment Tool , ISTH-BAT , International Society of Thrombosis and Hemostasis BAT II. Indications Screening for congenital s III. Precautions and are poor for inherited platelet function disorders IV. Criteria Score 0: None or Trivial Score 1: More than 5 per year, or lasting >10 minutes Score 2: Only Score 3: Treated with packing, cauterization or antifibrinolytics Score 4: , replacement (e.g. Factor VIIa, PCC4), Cutaneous symptoms Score 0

2018 FP Notebook

4. ISTH Bleeding Assessment Tool

ISTH Bleeding Assessment Tool ISTH Bleeding Assessment Tool Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 ISTH Bleeding Assessment (...) Tool ISTH Bleeding Assessment Tool Aka: ISTH Bleeding Assessment Tool , ISTH-BAT , International Society of Thrombosis and Hemostasis BAT II. Indications Screening for congenital s III. Precautions and are poor for inherited platelet function disorders IV. Criteria Score 0: None or Trivial Score 1: More than 5 per year, or lasting >10 minutes Score 2: Only Score 3: Treated with packing, cauterization or antifibrinolytics Score 4: , replacement (e.g. Factor VIIa, PCC4), Cutaneous symptoms Score 0

2016 FP Notebook

5. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. (Full text)

Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. The ISTH bleeding assessment tool (ISTH-BAT) was developed to record bleeding symptoms and to aid diagnosis in patients with a possible bleeding disorder.To investigate the utility of the ISTH-BAT in predicting functional defects in platelet activation in participants with suspected inherited platelet function disorders.Participants with clinical (...) characteristic curve = 0.501 [95% confidence interval 0.372-0.630, P = 0.98] and odds ratio 1.01 [95% confidence interval 0.93-1.09, P = 0.91]).The ISTH-BAT is a powerful tool for documenting lifelong bleeding history. However, the score obtained is not predictive of the presence of a platelet defect on lumiaggregometry in patients with suspected inherited platelet function disorders.© 2013 International Society on Thrombosis and Haemostasis.

2013 Journal of Thrombosis and Haemostasis PubMed

6. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders (Full text)

Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders The ISTH bleeding assessment tool (ISTH-BAT) was developed to record bleeding symptoms and to aid diagnosis in patients with a possible bleeding disorder.To investigate the utility of the ISTH-BAT in predicting functional defects in platelet activation in participants with suspected inherited platelet function disorders.Participants with clinical (...) characteristic curve = 0.501 [95% confidence interval 0.372-0.630, P = 0.98] and odds ratio 1.01 [95% confidence interval 0.93-1.09, P = 0.91]).The ISTH-BAT is a powerful tool for documenting lifelong bleeding history. However, the score obtained is not predictive of the presence of a platelet defect on lumiaggregometry in patients with suspected inherited platelet function disorders.© 2013 International Society on Thrombosis and Haemostasis.

2013 Journal of Thrombosis and Haemostasis PubMed

7. Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice. (Full text)

Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice. Diagnosing mild bleeding disorders (BDs) in children is difficult. Bleeding scores (BSs) have been proposed for obtaining standardized quantitative histories.To compare the Canadian pediatric bleeding questionnaire (PBQ) with the new ISTH bleeding assessment tool (ISTH BAT) for the determination of BS in a routine pediatric outpatient (...) no BD and VWD (P = 0.0001), but the area under the receiver characteristics curve to detect any mild BD was only 0.76. Despite the inherited nature of the BD, a family score did not increase the ability to discriminate between no BD and VWD (P = 0.2052). There was no significant difference between the two tools used (P = 0.3253) or simple qualitative criteria, such as yes/no questions regarding bleeding (P = 0.3477).The two tools translated into German did not differ substantially. Both were able

2012 Journal of Thrombosis and Haemostasis PubMed

8. Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice (Full text)

. Screening modalities included the ISTH Bleeding Assessment Tool (ISTH-BAT), PT, aPTT, TT, Euglobulin Lysis Time (ELT), and Platelet Function Analyser (PFA).In 21 of 240 (8.8%) patients reporting bleeding symptoms, hemostatic abnormalities were found, including 7 reduced coagulation factor levels, 10 platelet function abnormalities, and 4 reduced vWF levels. In comparison, 10 of 95 (10.5%) patients not reporting bleeding symptoms had abnormalities. The ISTH-BAT could not identify patients (...) Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice Patients with mild bleeding disorders are at risk of perioperative bleeding, but screening for these disorders remains challenging.We aimed to assess the prevalence of hemostatic abnormalities in patients with and without reported bleeding symptoms on a preoperative questionnaire, consisting of guideline-proposed questions, and appraised the diagnostic value of several screening modalities

2018 Research and Practice in Thrombosis and Haemostasis PubMed

9. Significant gynecological bleeding in women with low von Willebrand factor levels (Full text)

Significant gynecological bleeding in women with low von Willebrand factor levels Gynecological bleeding is frequently reported in women with von Willebrand disease (VWD). Low von Willebrand factor (VWF) may be associated with significant bleeding phenotype despite only mild plasma VWF reductions. The contribution of gynecological bleeding to this phenotype has yet to be described. The optimal clinical bleeding assessment tool (BAT) to evaluate bleeding remains unclear. Using a standardized (...) approach to phenotypic assessment, we evaluated gynecological bleeding and directly compared the Condensed Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD (Condensed MCMDM-1 VWD) and International Society on Thrombosis and Haemostasis (ISTH) BAT scores in 120 women enrolled in the Low von Willebrand in Ireland Cohort study. Heavy menstrual bleeding (HMB) was reported in 89% of female participants; 45.8% developed iron deficiency. Using identical data, Condensed MCMDM-1 VWD

2018 Blood advances PubMed

10. A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding (Full text)

Assessment Tool (ISTH-BAT). DDAVP (0.3 μg/kg) was administered either IV or subcutaneously (SC), and blood was drawn at baseline and 1, 2, and 4 hours postadministration. Blood was assessed for factor VIII (FVIII) level, von Willebrand factor (VWF) antigen (VWF:Ag), VWF activity (VWF:RCo or VWF:GPIbM), thromboelastography (TEG), and thrombin generation assay (TGA) at all points, and for VWF propeptide (VWFpp):Ag ratio and ABO blood type at baseline. Carriers were older than control patients (median age (...) A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding The cause of hemophilia A carrier bleeding is not well established. Desmopressin (DDAVP), used clinically to treat or prevent bleeding, can also be used as a medical stress surrogate. This study's objective was to compare the response to DDAVP in hemophilia A carriers with that in normal control patients. Bleeding was assessed by the International Society on Thrombosis and Hemostasis Bleeding

2018 Blood advances PubMed

11. Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding. (Full text)

-16 years) with Type 1 (n = 60), 2 (n = 44), and 3 (n = 9) VWD with von Willebrand factor (VWF) antigen and/or VWF ristocetin cofactor levels ≤ 30 U/dL from a nation-wide cross-sectional study ("Willebrand in the Netherlands" study). Bleeding severity and frequency were determined using the International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT) with supplementary pediatric-specific bleeding symptoms (umbilical stump bleeding, cephalohematoma, cheek hematoma (...) Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding. The bleeding phenotype of children with von Willebrand disease (VWD) needs to be characterized in detail to facilitate diagnosis during childhood and aid in the planning and assessment of treatment strategies. The objective was to evaluate the occurrence, type, and severity of bleeding in a large cohort of children with moderate and severe VWD. We included 113 children (aged 0

2015 American journal of hematology PubMed

12. Is there a role for DOAC level monitoring in clinical practice?

to have the clear advantage in terms of rapid, reliable, widely-available laboratory testing and drug reversal agents. For an anticoagulated patient presenting with an acute bleed, thromboembolic event, and/or a need for an urgent invasive procedure, the evidence and tools available to reliably assess levels of anticoagulation and reverse continue to buoy warfarin’s modern clinical relevance. A DOAC lab measurement analogous to prothrombin time (PT)/international normal ratio (INR) would be a valuable (...) , a switch to another DOAC or warfarin/enoxaparin should be considered rather than increasing the dose of the original DOAC 11,32 . Acute Bleed/Hemorrhage: The Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis (ISTH) recommends administration of an antidote for patients presenting with clinically significant bleeding & a DOAC concentration > 50 ng/mL 33,34 . In cases of a hemodynamically unstable/life-threatening bleeding event, in addition

2019 Clinical Correlations

13. Management of Antiplatelet Therapy among Patients on Antiplatelet Therapy for Coronary or Cerebrovascular Disease

of Bias tool. 11 However, we identified no trials. Cohort studies were assessed on design (eg, retrospective vs prospective), representativeness of the enrolled subjects, assessments of the exposure and outcome, follow-up rates, and statistical methods. DATA SYNTHESIS Data were too heterogeneous to support statistical pooling. We plotted MACE and bleeding outcomes by the preoperative APT and the perioperative management, and assessed for trends or patterns. We then assessed possible explanations (...) the impact of APT management for the wide range of procedures. It is likely that factors other than the perioperative management of APT play a role in differences in bleeding and MACE rates observed between studies. The strength (or quality) of the evidence was insufficient for all key questions. Management of Antiplatelet Therapy Evidence-based Synthesis Program 3 Applicability Several studies specifically assessed Veterans, including the largest study. Even though the remaining studies were not in VA

2017 Veterans Affairs Evidence-based Synthesis Program Reports

14. Standardized Library of Atrial Fibrillation Outcome Measures

, or intramuscular with compartment syndrome AND/OR bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of blood. ISTH definition (8) A-3 OMF CATEGORY OUTCOME MEASURE DEFINITION REFERENCE Events of Interest Periprocedural bleeding (any bleeding during 12-month interval which occurs within 30d of procedure) Major bleeding: Fatal bleeding AND/OR symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular (...) treatment for bleeding; change in antithrombotic therapy (including interruption or discontinuation). Minor bleeding: All nonmajor bleeds. Minor bleeds are further divided into clinically relevant and not. Note: Registries should clearly report how they communicate with patients (phone, in- person visit) to obtain information on bleeding events. ISTH definition (8) A-4 OMF CATEGORY OUTCOME MEASURE DEFINITION REFERENCE Events of Interest Myocardial infarction The term acute myocardial infarction (MI

2018 Effective Health Care Program (AHRQ)

15. Arrhythmias in Congenital Heart Disease: A Position Paper of EHRA, AEPC, and ESC Working Group on Grown-up Congenital Heart Disease

modification . . . . . . . 6 Ventriculararrhythmias 6 Stablemonomorphicventriculartachycardia 6 Polymorphicventriculartachycardia 6 Work-up of patients with congenital heart disease andarrhythmias 6 Acute assessment of the congenital heart disease patientpresentingwitharrhythmia 7 Collaboration between adults with congenital heart diseaseandarrhythmiaspecialists 7 General assessment of the congenital heart disease patientwitharrhythmias 7 Arrhythmiamanagementviaimplanteddevices 8 Imaging requirements (...) to guidelines, we have opted for an easier and Arrhythmias in congenital heart disease 3 Downloaded from https://academic.oup.com/europace/advance-article-abstract/doi/10.1093/europace/eux380/4944677 by guest on 21 March 2018user-friendly system of ranking using ‘coloured hearts’ that should allow physicians to easily assess current status of evidence and conse- quent guidance (Table1). Thus, a ‘green heart’ indicates a recommended statement or rec- ommended/indicated treatment (or procedure) and is based

2017 Heart Rhythm Society

16. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

Journal Info > > Guideline for Reversal of Antithrombotics in Intracranial He... Email to a Colleague Colleague's E-mail is Invalid Your Name: (optional) Your Email: Colleague's Email: Separate multiple e-mails with a (;). Message: Thought you might appreciate this item(s) I saw at Critical Care Medicine. Send a copy to your email Your message has been successfully sent to your colleague. Some error has occurred while processing your request. Please try after some time. Article Tools Share (...) , Centra Lynchburg General Hospital, Lynchburg, VA. The Neurocritical Care Society and Society of Critical Care Medicine affirm the value of this guideline as an educational tool for clinicians. The American Association of Neurological Surgeons and Congress of Neurological Surgeons affirm the educational benefit of this document. Drs. Frontera and Lewin ( Guideline cochairs) contributed equally to this article. Dr. Aisiku serves on the National Advisory Board for the Medicines Company. Dr. Lewin III

2016 Society of Critical Care Medicine

17. Initial Diagnostic Workup of Acute Leukemia

using an evidence-based meth- odology intended to meet recommendations for a report from the Institute of Medicine. 9 This guideline is based on the results of a systematic review (SR) of available evidence. A detailed description of the methods and SR (including the quality assessment and complete analysis of the evidence) used to create this guideline can be found in the supplemental digital content, which also includes 24 tables and 2 ?gure ?les, at www.archivesofpathology.org in the October 2017 (...) with, and grants received from, Seattle Genetics, Inc (Bothell, Washington), and GlaxoSmithKline plc (Brentford, United Kingdom). Most of the EP (6 of 11 members) was assessed as having no relevant con?icts of interest. The CAP and ASH provided funding for the administra- tionoftheproject;noindustryfundswereusedinthedevelopment of the guideline. All panel members volunteered their time and were not compensated for their involvement, except for the contracted methodologist. Please see the SDC for full details

2016 College of American Pathologists

18. Aortic Diseases

with the medical care of patients with this pathology.Selectedexpertsinthe?eldundertookacomprehensive reviewofthepublishedevidenceformanagement(includingdiagno- sis, treatment, prevention and rehabilitation) of a given condition accordingto ESC Committee forPractice Guidelines (CPG)policy. A critical evaluation of diagnostic and therapeutic procedures was performed including assessment of the risk-bene?t-ratio. Estimates of expected health outcomes for larger populations wereincluded, where data exist (...) , including the medical, endovascular, and surgical approaches,which areoften combined. In addition, genetic disorders, congenital abnormalities, aortic aneurysms, and AD are discussedinmoredetail. In the following section, the normal- and the ageing aorta are described. Assessment of the aorta includes clinical examination and laboratory testing, but is based mainly on imaging techniques usingultrasound,computedtomography(CT),andMRI.Endovascu- lar therapies are playing an increasingly important role

2014 European Society of Cardiology

19. Diagnosis and management of von Willebrand disease

1 VWD patients in compar- ison with unaffected family members (Tosetto et al, 2006). To improve decisions regarding the signi?cance of bleeding symptoms, attempts have been made to develop a standard- ized bleeding assessment tool (BAT), with the Scienti?c and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) BAT being the most recent iteration (Rodeghiero et al, 2010; Rydz & James, 2012). These tools can help predict the likelihood of a bleed- ing (...) for mother and child. Obstetrical and Gynecological Survey, 53, 450– 455. Rodeghiero, F., Tosetto, A., Abshire, T., Arnold, D.M., Coller, B., James, P., Neunert, C., Lillic- rap, D., On Behalf Of the ISTH/SSC Joint VWF & Perinatal/Pediatric Hemostasis Subcommittees Working Group (2010) ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of Throm- bosis and Haemostasis, 8, 2063–2065. Rydz, N. & James, P.D. (2012

2014 United Kingdom Haemophilia Centre Doctors' Organisation

20. Hemostatic abnormalities in patients with ehlers-danlos syndrome. (PubMed)

of connective tissue disorders affecting skin, bones, vessels, and other organs. Patients with EDS have an increased risk of bleeding, but a comprehensive study of hemostasis in EDS patients is lacking. Objective To investigate the bleeding tendency of a cohort of patients with EDS by using the Bleeding Assessment Tool of the ISTH, the bleeding severity score (BSS). Methods The BSS was defined as abnormal when it was ≥ 4 in men and ≥ 6 in women. Patients with a bleeding tendency were compared with those (...) Hemostatic abnormalities in patients with ehlers-danlos syndrome. Essentials Ehlers-Danlos Syndrome (EDS) is a rare heterogeneous group of inherited collagen disorders. A cohort of EDS patients was investigated for bleeding tendency and hemostatic abnormalities. EDS is associated with an increased risk of bleeding. EDS patients have platelet function abnormalities, whose severity correlates with bleeding risk. SUMMARY: Background Ehlers-Danlos syndrome (EDS) includes a heterogeneous group

2018 Journal of Thrombosis and Haemostasis

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>